Heat-shock protein HSPB1 attenuates microRNA miR-1 expression thereby restoring oncogenic pathways in prostate cancer cells

Anticancer Research

Volumn 34, Issue 7, 2014, Pages 3475-3480

  Stope, Matthias B ^a   Stender, Christian ^a   Schubert, Tina ^a   Peters, Stefanie ^a   Weiss, Martin ^a   Ziegler, Patrick ^b   Zimmermann, Uwe ^a   Walther, Reinhard ^a   Burchardt, Martin ^a  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Heat shock protein HSPB1; MicroRNA miR 1; Oncogenesis; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; HEAT SHOCK PROTEIN 27; MICRORNA 1; TRANSFORMING GROWTH FACTOR BETA1; HSPB1 PROTEIN, HUMAN; MICRORNA; MIRN1 MICRORNA, HUMAN;

ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CELL PROLIFERATION ASSAY; CELL PROTECTION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; LNCAP CELL LINE; MALE; PROSTATE CANCER CELL LINE; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; BIOSYNTHESIS; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL GROWTH; DISEASE COURSE; GENETICS; HEAT-SHOCK PROTEIN HSPB1; METABOLISM; MICRORNA MIR-1; MOLECULAR CLONING; PATHOLOGY; PHYSIOLOGY; PROSTATE CANCER; TUMOR CELL LINE;

HEAT-SHOCK PROTEIN HSPB1; MICRORNA MIR-1; ONCOGENESIS; PROSTATE CANCER;

CELL GROWTH PROCESSES; CELL LINE, TUMOR; CLONING, MOLECULAR; DISEASE PROGRESSION; HSP27 HEAT-SHOCK PROTEINS; HUMANS; MALE; MICRORNAS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84906314037     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Calderwood SK, Khaleque MA, Sawyer DB and Ciocca DR: Heat-shock proteins in cancer: Chaperones of tumorigenesis. Trends Biochem Sci 31: 164-172, 2006.
2. Lu S, Tan Z, Wortman M and Dong Z: Regulation of heat-shock protein 70-1 expression by androgen receptor and its signaling in human prostate cancer cells. Int J Oncol 36: 459-467, 2010.
3. So A, Hadaschik B, Sowery R and Gleave M: The role of stress proteins in prostate cancer. Curr Genomics 8: 252-261, 2007.
4. Zoubeidi A, Zardan A, Beraldi E, Fazli E, Sowery R, Rennie P, Nelson C and Gleave M: Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res 67: 10455-10465, 2007.
5. Andrieu C, Taieb D, Baylot V, Ettinger S, Soubeyran P, De-Thonel A, Nelson C, So A, Fazli L, Bladou F, Gleave M, Iovanna JL and Rocchi P: Heat-shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E. Oncogene 29: 1883-1896, 2010.
6. Foster CS, Dodson AR, Ambroisine L, Fisher G, Moller H, Clark J, Attard G, De-Bono J, Scardino P, Reuter YE, Cooper CS, Bernay DM and Cuzick J: Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS gene rearrangement. Br J Cancer 101: 1137-1144, 2009.
7. Stope MB, Schubert T, Staar D, Rönnau C, Streitbörger A, Kroeger N, Kubisch C, Zimmermann U, Walther R and Burchardt M: Effect of the heat-shock protein HSP27 on androgen receptor expression and function in prostate cancer cells. World J Urol 30: 327-331, 2012.
8. Baylot V, Katsogiannou M, Andrieu C, Taieb D, Acunzo J, Giusiano S, Fazli L, Gleave M, Garrido C and Rocchi P: Targeting TCTP as a new therapeutic strategy in castration-resistant prostate cancer. Mol Ther 20: 2244-2256, 2012.
9. Ottman R, Nguyen C, Lorch R and Chakrabarti R: MicroRNA expressions associated with progression of prostate cancer cells to antiandrogen therapy resistance. Mol Cancer 13: 1-21, 2014.
10. Shi G, Ye D, Yao X, Zhang S, Dai B, Zhang H, Shen Y, Zhu Y, Zhu Y, Xiao W and Ma C: Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgenindependent prostate cancer PC3 cells. Acta Pharmacol Sin 31: 867-873, 2010.
11. Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K and Gleave M: Heat-shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 64: 6595-6602, 2004.
12. Cornford PA, Dodson AR, Parsons KF, Desmond AD, Woolfenden A, Fordham M, Neoptolemos JP, Ke Y and Foster CS: Heat-shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 60: 7099-7105, 2000.
13. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, Yfantis HG, Stephens RM and Croce CM: Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 68: 6162-6170, 2008.
14. Pekarik V, Gumulec J, Masarik M, Kizek R and Adam V: Prostate cancer, miRNAs, metallothioneins and resistance to cytostatic drugs. Curr Med Chem 20: 534-544, 2013.
15. Catto JW, Alcaraz A, Bjartell AS, Vere White R de, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T and Visakorpi T: MicroRNA in prostate, bladder, and kidney cancer: A systematic review. Eur Urol 59: 671-681, 2011.
16. Boll K, Reiche K, Kasack K, Mörbt N, Kretzschmar AK, Tomm JM, Verhaegh G, Schalken J, Bergen M von, Horn F and Hackermüller J: miR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are down-regulated in prostate carcinoma. Oncogene 32: 277-285, 2012.
17. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W and Tuschl T: Identification of tissue-specific microRNAs from mouse. Curr Biol 12: 735-739, 2002.
18. Hudson RS, Yi M, Esposito D, Watkins SK, Hurwitz AA, Yfantis HG, Lee DH, Borin JF, Naslund MJ, Alexander RB, Dorsey TH, Stephens RM, Croce CM and Ambs S: MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucl Acids Res 40: 3689-3703, 2012.
19. Kojima S, Chiyomaru T, Kawakami K, Yoshino H, Enokida H, Nohata N, Fuse M, Ichikawa T, Naya M, Nakagawa M and Seki N: Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. Br J Cancer 106: 405-413, 2012.
20. Liu Y, Yin JJ, Abou-Kheir W, Hynes PG, Casey OM, Fang L, Yi M, Stephens RM, Seng V, Sheppard-Tillman H, Martin P and Kelly K: miR-1 and miR-200 inhibit EMT via slug-dependent and tumorigenesis via slug-independent mechanisms. Oncogene 32: 296-306, 2013.
21. Stope MB, Rönnau C, Schubert T, Staar D, Bradl J, Ziegler P, Streitbörger A, Kroeger N, Zimmermann U, Walther R, Burchardt M and Börgermann C: Transforming growth factor β in prostate cancer. Cellular effects and basic molecular mechanisms. Urologe A 52: 378-383, 2013.
22. Tamburrino L, Salvianti F, Marchiani S, Pinzani P, Nesi G, Serni S, Forti G and Baldi E: Androgen receptor (AR) expression in prostate cancer and progression of the tumor: Lessons from cell lines, animal models and human specimens. Steroids 77: 996-1001, 2012.
23. Stope MB, Bradl J, Peters S, Streitbörger A, Weiss M, Zimmermann U, Walther R, Lillig CH and Burchardt M: Shortened isoforms of the androgen receptor are regulated by the cytoprotective heat-shock protein HSPB1 and the tumor-suppressive microRNA miR-1 in prostate cancer cells. Anticancer Res 33: 4921-4926, 2013.
24. Zhu B and Kyprianou N: Transforming growth factor beta and prostate cancer. Cancer Treat Res 126: 157-173, 2005.
25. Kang HY, Huang KE, Chang SY, Ma WL, Lin WJ and Chang C: Differential modulation of androgen receptor-mediated transactivation by Smad3 and tumor suppressor Smad4. J Biol Chem 277: 43749-43756, 2002.
26. Leone V, D'Angelo D, Rubio I, Freitas PM de, Federico A, Colamaio M, Pallante P, Medeiros-Neto G and Fusco A: miR-1 is a tumor suppressor in thyroid carcinogenesis targeting CCND2, CXCR4, and SDF-1. J Clin Endocrinol Metab 96: 1388-1398, 2011.
27. Gan L, Wang J, Xu H and Yang X: Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling. Prostate 71: 1158-1166, 2011.